Equities Analysts Offer Predictions for PBH Q4 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for shares of Prestige Consumer Healthcare in a research report issued on Thursday, November 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.28 for the quarter, up from their previous forecast of $1.24. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q2 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.25 EPS, FY2026 earnings at $4.74 EPS and FY2027 earnings at $4.96 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company’s revenue was down .9% on a year-over-year basis. During the same period last year, the company earned $1.07 earnings per share.

A number of other equities analysts have also weighed in on PBH. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $84.70 on Monday. The stock has a market capitalization of $4.18 billion, a P/E ratio of 20.61, a price-to-earnings-growth ratio of 2.39 and a beta of 0.49. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36. The firm’s fifty day simple moving average is $75.93 and its two-hundred day simple moving average is $71.48. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. Ariel Investments LLC lifted its holdings in Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after buying an additional 274,212 shares during the period. Victory Capital Management Inc. grew its position in shares of Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after buying an additional 171,357 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Prestige Consumer Healthcare by 19.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after acquiring an additional 255,045 shares during the period. Geode Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after acquiring an additional 50,961 shares during the last quarter. Finally, Congress Asset Management Co. grew its holdings in Prestige Consumer Healthcare by 7.8% during the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after purchasing an additional 62,411 shares during the period. Institutional investors own 99.95% of the company’s stock.

Insiders Place Their Bets

In other news, insider William P’pool sold 8,987 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 over the last three months. Company insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.